Quick editorial update: We spoke to the people at Augma and below is their response for the reason they chose to use HA in their new CS composite graft, Bond Apatite.
Regarding long term space maintainers: Actually b-TCP could have been used, however we instead chose to use HA in a controlled particle size distribution with our Biphasic Calcium Sulfate matrix in Bond Apatite®. The HA was chosen because it enables the use of the graft in a large diversity of bone defects without any concerns about whether it will give sufficient space maintenance for wide defects with less bony wall support. If the clinician did not make the right evaluation about what should be the best space maintainer for a specific case, the material will compensate for this and give good three dimensional stabilization due to the HA. The HA was used as an innocuous space maintainer; it has no influence on the bone growth, it just provides space maintenance for the Biphasic Calcium Sulfate, which is more than 60% of the graft, and which resorbs into the patient’s own bone in a large defect.
In addition, it is important to note that the Calcium Sulfate itself is different than any other CS used in grafting products. The CS used in the European composite graft you referred to that is mixed with b-TCP, is a CS Hemihydrate, commonly used in dental grafting over the years. However, Bond Apatite’s CS is Biphasic Calcium Sulfate. Biphasic Calcium Sulfate is a patent of Augma Biomaterials and provides improved handling and results over other forms of CS, both in terms of handling and results. On the handling side, CS Hemihydrate does not know how to set and harden in blood and saliva in an amount of time conducive to a surgical procedure. Biphasic Calcium Sulfate, on the other hand, sets and hardens in situ in 3 minutes, providing improved handling and a more comfortable work flow. On the results end, Biphasic Calcium Sulfate’s resorption profile matches the bone growth profile, while CS Hemihydrate’s does not. This means the Biphasic Calcium Sulfate in Bond Apatite® is simultaneously replaced by the patient’s own bone as it resorbs, providing a better quality and quantity of bone in a predictable amount of time.